Pacific Biosciences Of California (PACB) Cash & Equivalents (2010 - 2026)

Pacific Biosciences Of California has reported Cash & Equivalents for 17 years, with the latest figure at $56.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 3.82% year-over-year to $56.3 million; the trailing twelve-month figure through Mar 2026 stood at $56.3 million (down 3.82% YoY), and the FY2025 full-year result was $63.7 million, up 15.06% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $56.3 million, down from $63.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $428.6 million in Q1 2022, with the low at $54.8 million in Q2 2025.
• Average Cash & Equivalents over 5 years is $182.1 million, with a median of $99.5 million recorded in 2024.
• Year-over-year, Cash & Equivalents climbed 26.68% in 2023 and slumped 79.78% in 2024.
• Tracing PACB's Cash & Equivalents over 5 years: stood at $325.1 million in 2022, then slumped by 44.66% to $179.9 million in 2023, then slumped by 69.22% to $55.4 million in 2024, then increased by 15.06% to $63.7 million in 2025, then decreased by 11.67% to $56.3 million in 2026.
• The last three Cash & Equivalents figures came in at $56.3 million (Q1 2026), $63.7 million (Q4 2025), and $56.5 million (Q3 2025), per Business Quant data.

Peer Comparison